New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 7, 2013
09:10 EDTAPPY, APPY, SNTI, SNTI, AEMD, AEMD, INO, INOPR Newswires to host a virtual conference
RetailInvestorConference is being held on February 7 with webcasted company presentations to begin at 9:15 am. Webcast Link
News For APPY;SNTI;AEMD;INO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 26, 2014
07:32 EDTINOBioCentury to hold a conference
21st Annual NewsMakers in the Biotech Industry Conference to be held in New York on September 26.
September 24, 2014
09:32 EDTAEMDAethlon Medical announces dengue virus treatment agreement
Subscribe for More Information
06:02 EDTINOInovio Ebola vaccine moving into human trial with GeneOne Life Science
Subscribe for More Information
September 22, 2014
10:31 EDTAEMDAethlon Medical receives notice of DARPA contract renewal
Aethlon Medical disclosed that the Defense Advanced Research Projects Agency has informed the company that it plans to exercise an option to proceed with year four of a five-year $5.9M contract that was awarded to Aethlon on September 30, 2011 under DARPA's Dialysis-Like Therapeutics program. The fourth year of Aethlon's DLT contract contains three milestones representing a potential of $669,292 in revenue opportunity. To date, Aethlon has invoiced $4.25M to DARPA for achieving twenty of twenty-three milestone objectives targeted in the first three years of the DLT program.
08:10 EDTINOInovio initiates phase I clinical trial in patients with aerodigestive cancers
Inovio announced it has initiated a phase I clinical trial in patients with aerodigestive cancers. The trial will evaluate the safety, tolerability, and immunogenicity of INO-3106. This immunotherapy targets human papillomavirus type 6, which causes most aerodigestive cancers. This study is part of Inovio's strategy to broadly expand clinical development of its DNA-based immune therapy products to treat different HPV types and the many diseases they cause. It is a phase I, open label compassionate study enrolling patients with invasive cancer who have exhausted all other treatment options. The study will test Inovio's immunotherapy, INO-3106, alone or in combination with DNA-based IL-12, Inovio's proprietary immune activator, in subjects with HPV-6 associated aerodigestive malignancies. Successful results could open a path to pursuing an FDA orphan designation for aerodigestive cancers.
September 19, 2014
10:53 EDTINO Options with increasing implied volatility: ESI INO VALE AGNC
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use